Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth ...

The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

French pharmaceutical giant Sanofi reported a sharp increase in second-quarter profit on Thursday, driven by higher net sales ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong ...

U.S. sales of Eylea HD and Eylea, treatments for eye conditions like wet age-related macular degeneration, decreased 25% in ...

Sanofi Consumer Healthcare said its growth was driven by successful product launches and the successful relaunch of two ...

Sanofi Consumer Healthcare India reports ₹220 crore revenue, ₹60 crore profit, driven by exports, product launches, and ...

Sanofi India's demerged entity, Sanofi Consumer Healthcare India, has reported a 28% year-on-year increase in Q2 revenue at ...

Sanofi Consumer Healthcare India surged 12.56% to Rs 5385 after the company announced strong financial results for the second quarter of 2025.

For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.

The deal with Arrowhead's Visirna Therapeutics subsidiary – which also includes $265 million in milestones tied to potential ...